Stock Scorecard



Stock Summary for Alkermes plc (ALKS) - $33.53 as of 3/28/2025 7:12:40 PM EST

Total Score

18 out of 30

Safety Score

61 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for ALKS

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ALKS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ALKS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ALKS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ALKS (61 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ALKS

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? 3/25/2025 4:44:00 PM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer 3/17/2025 11:05:00 AM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer - Zenas BioPharma ( NASDAQ:ZBIO ) 3/17/2025 11:05:00 AM
Why Is Alkermes ( ALKS ) Down 6.6% Since Last Earnings Report? 3/14/2025 3:30:00 PM
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - Grace Therapeutics ( NASDAQ:GRCE ) , Matinas BioPharma Hldgs ( AMEX:MTNB ) 3/11/2025 11:00:00 AM
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock? 3/3/2025 5:01:00 PM
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up 2/13/2025 3:58:00 PM
Alkermes ( ALKS ) Q4 Earnings and Revenues Surpass Estimates 2/12/2025 1:40:00 PM
What Analyst Projections for Key Metrics Reveal About Alkermes ( ALKS ) Q4 Earnings 2/10/2025 2:16:00 PM
Schizophrenia Drugs Market Size is Projected to Reach USD 12.33 Billion by 2033, Growing at a CAGR of 5.10%: Straits Research 1/22/2025 3:12:00 PM

Financial Details for ALKS

Company Overview

Ticker ALKS
Company Name Alkermes plc
Country USA
Description Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/29/2025

Stock Price History

Last Day Price 33.53
Price 4 Years Ago 23.26
Last Day Price Updated 3/28/2025 7:12:40 PM EST
Last Day Volume 1,096,782
Average Daily Volume 1,780,362
52-Week High 36.45
52-Week Low 22.90
Last Price to 52 Week Low 46.42%

Valuation Measures

Trailing PE 15.31
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 36.50
Free Cash Flow Ratio 7.26
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 3.04
Total Cash Per Share 4.62
Book Value Per Share Most Recent Quarter 9.03
Price to Book Ratio 3.74
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 3.52
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 162,614,000
Market Capitalization 5,452,447,420
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.59%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 33.10%
Annual Earnings Growth 3.18%
Reported EPS 12 Trailing Months 2.19
Reported EPS Past Year 2.90
Reported EPS Prior Year 1.42
Net Income Twelve Trailing Months 367,070,000
Net Income Past Year 367,070,000
Net Income Prior Year 355,757,000
Quarterly Revenue Growth YOY 13.90%
5-Year Revenue Growth 6.13%
Operating Margin Twelve Trailing Months 37.80%

Balance Sheet

Total Cash Most Recent Quarter 751,668,000
Total Cash Past Year 751,668,000
Total Cash Prior Year 745,048,000
Net Cash Position Most Recent Quarter 465,845,000
Net Cash Position Past Year 463,938,000
Long Term Debt Past Year 287,730,000
Long Term Debt Prior Year 287,730,000
Total Debt Most Recent Quarter 285,823,000
Equity to Debt Ratio Past Year 0.84
Equity to Debt Ratio Most Recent Quarter 0.84
Total Stockholder Equity Past Year 1,464,977,000
Total Stockholder Equity Prior Year 1,254,763,000
Total Stockholder Equity Most Recent Quarter 1,464,977,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 405,640,000
Free Cash Flow Per Share Twelve Trailing Months 2.49
Free Cash Flow Past Year 405,640,000
Free Cash Flow Prior Year 353,305,000

Options

Put/Call Ratio 685.67
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.22
MACD Signal 0.33
20-Day Bollinger Lower Band 26.52
20-Day Bollinger Middle Band 31.51
20-Day Bollinger Upper Band 36.50
Beta 0.58
RSI 52.77
50-Day SMA 28.03
150-Day SMA 27.63
200-Day SMA 27.32

System

Modified 3/28/2025 5:10:09 PM EST